Sino Partners provides health economics modelling, program evaluation and policy advocacy support for Chinese health and life sciences businesses seeking PBS/MBS reimbursement, government procurement and evidence-based market positioning in Oceania.
In Australia and New Zealand's government-funded health systems, clinical efficacy alone does not determine market success. Reimbursement, procurement and formulary decisions are driven by health economic evidence - demonstrating value for money, cost-effectiveness and budget impact alongside clinical outcomes.
For Chinese health technology businesses seeking PBS listing, MBS item development, NDIS reimbursement or government procurement, a robust health economics evidence strategy is not optional. Sino Partners provides this capability, combining economic modelling expertise with deep knowledge of Australian and New Zealand health system decision-making frameworks.
Evidence generation and economic analysis for Chinese healthcare businesses navigating Oceania's reimbursement and procurement environment.
Australia's Pharmaceutical Benefits Advisory Committee (PBAC) requires rigorous health economic evidence for all PBS listing applications. A well-constructed economic submission that demonstrates cost-effectiveness and acceptable budget impact is the foundation of a successful PBS listing.
Developing new MBS items for Chinese medical devices and diagnostics requires demonstration of comparative effectiveness and cost-effectiveness to the Medical Services Advisory Committee (MSAC). Sino Partners designs the evidence strategy and supports the MSAC application process.
Chinese assistive technology and AgeTech businesses seeking NDIS reimbursement need to demonstrate that their products meet the NDIS Assistive Technology list requirements and deliver value for money for NDIS participants.
Chinese businesses operating in Australia's health system often need independent program evaluation to demonstrate impact, inform scale-up decisions or support funding applications. Sino Partners designs and conducts rigorous economic evaluations of health programs and technology deployments.
Assess the existing clinical and economic evidence base for your product or program against PBAC, MSAC or NDIA requirements.
Develop a targeted evidence generation strategy that builds the economic case required for your specific reimbursement or procurement objective.
Execute health economic modelling, literature reviews and budget impact analysis to generate submission-ready evidence packages.
Prepare and submit economic evidence packages, and provide active support through the regulatory assessment process.
Deep working knowledge of PBAC and MSAC evidentiary requirements and decision-making frameworks - built through practical submission experience.
Understanding of both Chinese health economic frameworks and Australian/New Zealand HTA requirements - enabling evidence translation across systems.
Our health economics work is always connected to commercial strategy - ensuring the evidence base supports pricing, market access and reimbursement decisions.
Health economic models built to international standards (ISPOR guidelines) that will withstand scrutiny from PBAC, MSAC and NDIA reviewers.
Current intelligence on PBAC, MSAC and NDIA policy directions, reimbursement priorities and decision-making criteria.
Established relationships with health economists, clinician researchers and regulatory advisors across Australia and New Zealand.
Contact our health economics team to discuss your PBS, MBS or NDIS reimbursement strategy.
Start a Conversation →